Introduction
COPD, the primary cause of which is tobacco smoke, is a preventable and treatable disease. 1, 2 This chronic disease has gained interest as a major public health concern, and it is now considered as one of the leading causes of disability. 2 To better investigate this chronic disease, it would be wise to refer to the World Health Organization's most recent categorization of its natural history (http:// www.who.int/classifications/icf/en/, Accessed October 9, 2015) , reporting 3 evolutionary phases: deficiency, incapacity, and handicap. Although mechanisms of COPD de-ficiency have already been extensively explored, [3] [4] [5] those of the remaining 2 phases are understudied. 6 The assessment of incapacity is considered important, because it alone can predict the prospective functioning of the subject. 7, 8 This is the determination of exercise ease through data from an outside test, such as the 6-min walk test (6MWT). 7, 8 The skill of walking is a reflection of the ability to maintain a number of daily life activities for patients. 7, 8 Therefore, it is an important quality-of-life (QOL) component. 7, 8 The handicap, which is the psychosocial impact of the chronic disease, can be objectively evaluated by the assessment of QOL 9 and/or physical activity status. 10 In a previous local study, 3 aiming to investigate the oxidative stress associated with tobacco smoke, the authors recommended evaluating its effects with submaximal exercise capacity and QOL. Finally, an integrative vision was advanced to evaluate subjects with COPD, through the BODE index, which is a simple multidimensional grading system predicting the risk of death. 11 Recently, the American Thoracic Society/European Respiratory Society 6 have recommended studies that contribute to a better understanding of COPD pathogenesis and impact and that elucidate pathways driving the chronic inflammatory response and oxidative stress that lead to the abnormalities characteristic of COPD. The present casecontrol study aimed to add to the current body of literature by evaluating the submaximal exercise, the QOL, and the blood and lung oxidative stress biomarker data of smokers free from COPD (non-COPD) and with COPD. The main null hypothesis is that there will be no difference between submaximal data mean values in both groups.
Populations and Methods
A part of the present study methodology was previously published in another study 3 that aimed to investigate oxidative stress in the blood or lungs associated with tobacco smoke and to evaluate its effect with pulmonary function data and its relation to physical activity.
Study Design
This was a case-control study performed from April to November 2013 in Farhat Hached Hospital (Sousse, Tunisia). More information about the city and the prevalence of smoking and COPD in that region was published previously. 3 In brief, 7.8% of the local population Ն40 y old had COPD. 3 The study was conducted in accordance with the Declaration of Helsinki. Participants provided written consent, and the study protocol was approved by the ethics committee of the hospital (approval 2204/2013).
Sample Size
The null hypothesis 12 was H 0 : m 1 ϭ m 2 , and the alternative hypothesis was H a : m 1 ϭ m 2 ϩ d, where d is the difference between 2 means, and n 1 and n 2 are the sample sizes for the non-COPD and COPD groups of smokers, such that N ϭ n 1 ϩ n 2 . The required sample size was estimated using a specific formula 12 (detailed in the supplemental materials at http://www.rcjournal.com) to detect a difference between 2 means with a power of 99% and an ␣ level of 1%. The total sample size for the study was 32 smokers (16 non-COPD and 16 COPD).
Population
The population was described previously. 3 In brief, subjects with COPD were recruited from the local respiratory department. The non-COPD smoker sample was a convenience sample recruited from the staff of the local Faculty of Medicine and/or hospital as well as from acquaintances of people involved in the study.
Only male smokers (Ն5 pack-years, age 40 -60 y) free from asthma, allergies, pulmonary tuberculosis, or recent respiratory tract infection (within the last 7 d) were included. Additional exclusion criteria included narghile smokers 13 ; 6MWT contraindications 7, 8 (detailed in the supplementary data); diabetes lasting for Ͼ5 y; and rheumatologic, orthopedic, or surgical diseases interfering with walking. An acute response to inhaled bronchodilator
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Current knowledge
Recently, scholarly societies have recommended studies that contribute to a better understanding of COPD pathogenesis and impact and that elucidate pathways driving the chronic inflammatory response and oxidative stress that lead to the abnormalities characteristic of COPD.
What this paper contributes to our knowledge
Compared with the non-COPD group, the COPD group had significantly lower 6-min walk distance (6MWD) by ϳ97 m, lower physical activity scores, and worse quality-of-life scores. Compared with the non-COPD group, the COPD group had significantly lower levels of glutathione. Stress oxidative biomarkers were correlated with 6MWD (malondialdehyde for the COPD group and glutathione for the non-COPD group) and quality-of-life scores (malondialdehyde for the COPD group and F ENO for the non-COPD group).
(Ͼ500 mL and 20% of FEV 1 or FVC) 14 and imperfect performance of the respiratory and 6MWT maneuvers (described in the supplementary data) were applied as exclusion criteria.
Smokers must have stopped smoking for Ն6 h, [15] [16] [17] [18] and they were asked to fast (no eating or drinking) for Ն10 h before coming to the hospital. 3 Smokers were asked not to participate in strenuous activity for 1 h before the fractional exhaled nitric oxide (F ENO ) measurements and 6MWT. [17] [18] [19] Smokers were divided into 2 groups, taking into account the post-bronchodilator FEV 1 /FVC ratio. Smokers with FEV 1 /FVC Ͼ0.70 were considered as free from COPD and qualified for the non-COPD smoker group. 4 Those with FEV 1 /FVC Յ0.70 were considered members of the COPD smoker group. 4 Subjects with COPD were clinically stable, with no worsening of symptoms, need of increase of medication, emergency care, or hospitalization within the previous 4 weeks. Duration of the COPD and medical treatments were recorded.
In order to avoid misinterpretation of plethysmographic data (especially reversibility test data) and/or F ENO data (influenced by inhaled glucocorticoids) 20 and/or stress oxidative data (influenced by vitamin use) 21 and/or 6-min walk distance (6MWD) (influenced by bronchodilator use), 22 
Study Protocol and Collected Data
Smokers were evaluated only for 1 day. The study protocol was in the following order: (1) fasting blood sample: malondialdehyde, glutathione, and protein sulfhydryl levels; (2) medical questionnaire (clinical data [sputum, cough, dyspnea, chest pain, wheezing, medical and surgical histories, and medication use], schooling and socioeconomic levels, and cigarette consumption), physical activity (household, sporting, and leisure activities), 10 and QOL (symptoms, activity, and impacts) 9 scores; (3) anthropometric data: age (chronological lung age), weight, height, and body mass index (BMI); (4) F ENO data; (5) plethysmographic data before/after bronchodilator: FVC, FEV 1 , FEV 1 /FVC, mid-maximal expiratory flow, slow vital capacity, thoracic gas volume, residual volume, total lung capacity, and estimated lung age; (6) 6MWT data: 6MWD (primary outcome), heart rate, S pO 2 , systolic blood pressure, diastolic blood pressure, dyspnea (visual analog scale), BODE index, 11 and estimated cardiorespiratory and muscle chain age. 3 Active smoking was assessed by series of questions about past and current activity. 3 Cigarette smoking and narghile use were evaluated, respectively, in pack-years and in narghile-years. 13 A narghile is a water pipe that is used to smoke a tobacco preparation burned by charcoal embers; the smoke is cooled by passing through water before being inhaled. 13 QOL was evaluated by the Saint George Respiratory Questionnaire (SGRQ). 9 An Arabic translation, but not validated, version of this questionnaire was applied. The SGRQ, self-administrated at the laboratory on the day of the 6MWT, is an airway disease-specific questionnaire divided into 3 subscales: symptoms, activity, and impacts (8, 16 , and 26 items, respectively). Scores were calculated using score calculation algorithms. Smokers were handed the questionnaire by one researcher (SBM) for completion.
A translated version of the Voorrips et al 10 physical activity questionnaire was filled out by each smoker, and household, sporting, and leisure activities were evaluated to yield a total physical activity score. The questionnaire was described previously. 3 According to the total physical activity score, 2 groups were defined (non-active [score Ͻ9.4] and active [score Ն9.4]).
Physical Examination
The following anthropometric data were verified, measured, or calculated: age (y), height (m), weight (kg), and BMI (kg/m 2 ). 3 Depending on BMI, the smokers were classified as non-obese (BMI Ͻ30) or obese (BMI Ն30). 3
Blood Sample
The blood sample technique was described previously. 3 Low levels of glutathione and protein sulfhydryl and a high level of malondialdehyde are signs of significant oxidative stress. 23 
F ENO and Plethysmographic Measurements
These 2 measurements were described previously. 3 F ENO (ppb), recently recommended as an oxidative biomarker that integrates both airway inflammation and lung function changes, 24, 25 was measured using an online method (electrochemical analyzer, Medisoft, Dinant, Belgium). 24 The mean of 3 reproducible values was retained. 24 The ple-thysmographic measurements were done according to American Thoracic Society/European Respiratory Society guidelines. 15 
6MWT Measurements
The 6MWT procedure was described extensively elsewhere. 7, 8, 17, 18, 28 It was conducted along a straight corridor according to American Thoracic Society/European Respiratory Society guidelines. 7, 8 All smokers performed the 6MWT for the first time with standardized encouragement. 7, 8 The following data were collected at rest and at the end of the 6MWT: heart rate (beats/min, % predicted maximum heart rate), S pO 2 (%), dyspnea (visual analog scale), and blood pressure (mm Hg). The 6MWD (m, % predicted) 28 and the number of stops during the test were noted.
The 6MWD lower limit of normal was calculated by subtracting 89 m from the predicted 6MWD value. 28 The estimated cardiorespiratory and muscle chain age (y) was calculated. 17, 18 Dyspnea during the 6MWT was quantified from 0 (no breathlessness) to 10 (maximum breathlessness) using the visual analog scale. 29 The following definitions, described elsewhere, 7, 8, 17, 18 ,28 were applied: (1) walk intolerance: abnormal 6MWD (less than the lower limit of normal) 28 and/or stops during the 6MWT 28 and/or abnormal dyspnea end (visual analog scale score Ͼ5/10) 29 ; (2) clinical desaturation: ⌬S pO 2 (equal to S pO 2 end Ϫ S pO 2 rest ) Ͼ5 points 28, 30 ; (3) chronotropic insufficiency: an ending heart rate of Ͻ60% predicted. 28, 31 
BODE Index
The BODE index, a multidimensional index ranging from 0 to 10 points, includes 4 items: BMI (B), degree of air flow obstruction (O) evaluated by the post-bronchodilator FEV 1 (%), dyspnea (D) evaluated by the Modified Medical Research Council scale, 11 and exercise (E) evaluated by the 6MWD (m). Higher scores indicate a greater risk of death. 11
Statistical Analysis
The analysis of variable distribution was performed using the Kolmogorov-Smirnov test. Quantitative data distributions were normal and expressed as mean Ϯ SD. For more precision, the oxidative stress biomarker data were expressed as mean Ϯ SE. Qualitative data were expressed as n (%).
The Mann-Whitney U test and chi-square test were used to compare the 2 groups' quantitative and qualitative data, respectively. The Wilcoxon test was used to compare each group's estimated lung age and estimated cardiorespiratory and muscle chain age with the chronological lung age.
Pearson product-moment correlation coefficients (r) evaluated the associations between oxidative stress biomarkers, submaximal exercise, QOL data and BODE index. An r Ͼ 0.70 was considered as high, r between 0.50 and 0.70 was considered good, r between 0.30 and 0.50 was considered fair, and r Ͻ 0.30 was considered to represent weak or no association. 32 All mathematical computations and statistical procedures were performed using Statistica (StatSoft, Inc., Tulsa, Oklahoma). Significance was set at .05. Table 1 presents the characteristics of the 2 groups. They were matched by age and by amounts of tobacco used. There was no significant statistical difference between the 2 groups in schooling or socioeconomic level or in clinical or pathological data. Compared with the non-COPD group, the COPD group included a lower percentage of obese smokers. Table 2 presents the plethysmographic data of the 2 groups. Compared with the non-COPD group, the COPD group had significantly lower FEV 1 , FEV 1 /FVC, and midmaximal expiratory flow. The estimated lung ages of the COPD and the non-COPD groups were significantly higher than their chronological lung ages: 85 Ϯ 18 y versus 49 Ϯ 5 y, respectively (P Ͻ .001) and 57 Ϯ 11 y versus 47 Ϯ 4 y (P ϭ .004). Four, 9, 2, and one subject of the COPD group had mild, moderate, severe, and very severe air flow limitation, respectively. Table 3 presents the 6MWT data of the 2 groups. Compared with the non-COPD group, the COPD group had a significantly lower 6MWD by ϳ97 m (ϳ14%). The 2 groups had similar 6MWT profiles.
Results
Characteristics of the 2 Smoker Groups
Evaluation of Deficiency
Evaluation of Incapacity
The estimated cardiorespiratory and muscle chain ages of the COPD and non-COPD groups were significantly higher than their chronological lung ages: 109 Ϯ 9 y versus 49 Ϯ 5 y, respectively (P Ͻ .001) and 86 Ϯ 16 y versus 47 Ϯ 4 y (P Ͻ .001).
Evaluation of the Social Disadvantage
There was no statistical significant difference between the 2 groups' physical activity status (see Table 1 ). Compared with the non-COPD group, the COPD group had significantly lower household, sporting, leisure, and physical activity scores and had significantly higher symptom, activity, impact, and QOL scores (see Table 1 ). For quantitative data, the Mann-Whitney U test was used (non-COPD vs COPD); for qualitative data, the chi-square test was used (non-COPD vs COPD). 
Oxidative Stress Biomarker Levels of the 2 Smoker Groups
No significant difference was found between the F ENO means Ϯ SE of the non-COPD and COPD groups (14 Ϯ 2 ppb vs 15 Ϯ 2 ppb, respectively, P ϭ .25). Figure 1 presents the oxidative stress biomarkers levels of the 2 groups. Compared with the non-COPD group, the COPD group had significantly lower levels of glutathione. However, malondialdehyde and protein sulfhydryl levels were similar for the 2 groups.
Relationship Between Stress Oxidative Biomarkers Levels, Submaximal Exercise, and QOL Data Table 4 presents the r value between oxidative stress biomarkers levels and 6MWT and physical activities and QOL data of the 2 groups. In the COPD group, only malondialdehyde was found to be significantly correlated with 6MWD, ⌬S pO 2 , symptom score, and QOL score. In the non-COPD group, F ENO was significantly correlated with leisure activity score, and glutathione was significantly correlated with 6MWD.
Discussion
In the present study, 2 age-and amount of tobacco used-matched groups of smokers of Ͼ5 pack-years (16 non-COPD and 16 COPD) were compared. Compared with the non-COPD group, the COPD group had significantly lower 6MWD (by ϳ14%) and physical activity score, significantly worse QOL, and lower glutathione level. The COPD group malondialdehyde level was significantly correlated with 6MWD, symptom score, and QOL score. The non-COPD group F ENO and glutathione levels were significantly correlated with leisure activity score and 6MWD, respectively.
Methodology
To the best of our knowledge, the present study is the first case-control study having as its main aim a comparison of incapacity and handicap data of 2 age-and amount of tobacco used-matched groups of smokers (COPD vs non-COPD) and an evaluation of the correlation between oxidative stress biomarker levels and their submaximal exercise and QOL data. For quantitative data, the Mann-Whitney U test was used (non-COPD vs COPD); for qualitative data, the chi-square test was used (non-COPD vs COPD). 6MWT ϭ 6-min walk test VAS ϭ visual analog scale 6MWD ϭ 6-min walk distance Discussion about the study design, inclusion and noninclusion criteria, choice of stress oxidant biomarkers, and plethysmographic measurements was published elsewhere. 3 Below, we discuss the 2 between-groups control factors (age and amount of tobacco used), the sample size calculation, and the choice of the SGRQ and the physical activity questionnaires.
Age and amount of tobacco used were applied as control factors to avoid misinterpretation of incapacity and handicap data. On the one hand, spirometric data and 6MWD are age-dependent. 28, 33 On the other hand, there were clear positive dose-effect relationships between smoking cumulative doses and, for example, QOL score (the higher the cumulative dose of smoking, the lower the QOL). 34 The present study calculated sample size (n ϭ 32; 16 COPD) is deemed to be satisfactory. However, it was smaller than those of Folchini et al 35 (cross-sectional study, n ϭ 45 COPD) and Lui et al 36 (case-control study, n ϭ 150; 100 COPD, 50 healthy smokers). The above studies aimed to evaluate the oxidative stress and the C-reactive protein in subjects with COPD and their correlation with COPD severity and BODE index 35 or the correlation between some serum inflammatory biomarkers and BODE index. 36 The SGRQ was applied because it is the only questionnaire that has a validated French version 37 and is the most widely used instrument for assessing health-related QOL (HRQOL). 9 The Voorrips physical activity questionnaire 10 was applied because it is frequently used to measure habitual physical activity, and it is a validated questionnaire for young as well as elderly people in apparently good health. 17, 28 It is important to highlight that the studies of Liu et al 36 and Folchini et al 35 have not evaluated their subjects' QOL and physical activity status. The choice of the 6MWT to evaluate submaximal exercise capacity and precautions taken during the walk are discussed in the supplementary data.
Study Limitations
The present study presented 3 limitations. The first concerned the control groups. In the present study, incapacity, handicap, and oxidative data of 2 groups (non-COPD and COPD smokers) were compared. Other studies have included 3 groups (COPD smokers, healthy smokers, and healthy non-smokers 16 or active and passive smokers and non-smokers 38 ). However, taking 3 groups into a single study seems to have little precedent in the literature and raises some questions, such as whether the prevalence of some clinical data (obesity, physical activity status, schooling level, socioeconomic level, clinical and pathological data) in the 3 groups is comparable. 3 The second limitation concerned the inclusion of obese smokers (see Table 1 ). Obesity induces systemic oxidative stress 39 and alters the 6MWD 40 and/or QOL. 41 As in the present study, the non-COPD group, compared with the COPD group, includes a significantly higher percentage of obese smokers; this could For the non-COPD group, n ϭ 16; for the COPD group, n ϭ 16. F ENO ϭ fractional exhaled nitric oxide MDA ϭ malondialdehyde PSH ϭ protein sulfhydryl GSH ϭ glutathione ⌬ ϭ 6-min walk test (end Ϫ resting) values QOL ϭ quality of life be a serious limitation (see Table 1 ). However, the percentage of included obese smokers (30%, 7 non-COPD and 2 COPD) (see Table 1 ) was similar to that described in the Tunisian general population 42 (obesity prevalence was 28%), and the present study sample could be a representative sample of the Tunisian population. In addition, the COPD sample of the present study was representative of the COPD population, where obesity prevalence is around 12.5%. 43 The last limitation concerns the use of a non-validated version of the SGRQ and the Voorrips questionnaire. In cases where questionnaires unadapted to the local culture are used, the psychometric characteristics in terms of validity, reliability, and sensibility could be a subject of caution.
Results
The World Health Organization classification of the natural history of chronic diseases (http://www.who.int/ classifications/icf/en/, Accessed October 9, 2015), such as COPD, reports 3 evolutionary phases: deficiency, incapacity, and handicap or social disadvantage. Below, we will discuss the 3 phases in addition to the integrative vision, including the BODE index.
Evaluation of Deficiency.
In the present study, compared with the non-COPD group, the COPD group had significantly lower flows and FEV 1 /FVC (see Table 2 ). The present result was similar to what has been previously published and discussed. 3, 44, 45 However, one interesting result of the present study was that smoking significantly accelerated lung aging of the 2 smoker groups, with a marked acceleration in the COPD group versus the non-COPD group. These results can be used to encourage smoking cessation. 27 Evaluation of Incapacity. Similar to other studies, [46] [47] [48] the present work reports a statistically significant decrease in submaximal exercise capacity in the COPD group compared with the non-COPD group. The 6MWD decrease of ϳ97 m is considered clinically important, since it was higher than the 6MWD 30-m minimal important difference in adults with chronic respiratory disease. 7, 8 For subjects with COPD, there is a strong association between shorter 6MWD and an increased risk of mortality 7, 8 and hospitalization and decreased HRQOL. 49 The non-COPD and COPD groups have similar heart rate data. However, they both included higher percentages of subjects with chronotropic insufficiency (see Table 3 ). It is established that heart rate responses may contribute to performance in the 6MWT in subjects with chronic respiratory disease. 7 The non-COPD and COPD groups have similar S pO 2 data and included a similar number of subjects with clinical desaturation (see Table 3 ). Oxygen desaturation during a 6MWT provides information regarding exercise-induced desaturation, disease severity, and disease progress. 8 Exercise-induced desaturation is associated with impaired daily physical activity, faster FEV 1 decline, and worse prognosis, 50 which supports its clinical importance.
The non-COPD and COPD groups have similar dyspnea data. However, they both included higher percentages of subjects with an abnormal dyspnea end (see Table 3 ). Dyspnea, an important determinant of the 6MWD in subjects with COPD, 51 reflects both the physiology of exercise limitation 52 and the impact of exercise limitation on daily life. 53 Another key outcome of the present study was that smoking significantly accelerated the 2 groups' cardiorespiratory muscle chain aging with a marked hastening in the COPD group versus the non-COPD group. It is an unwavering argument suggesting that a program of pulmonary rehabilitation is an excellent axis to follow not only for smokers with COPD but also in smokers free from COPD.
Evaluation of Handicap.
In the present study, as in others, [54] [55] [56] compared with the non-COPD group, the COPD group had a significantly worse QOL (see Table 1 ). For example, Agusti et al 56 found subjects with COPD to have a significantly lower QOL score when compared with control smokers (SGRQ mean Ϯ SD, 50 Ϯ 20 vs 21 Ϯ 12, respectively). Whereas almost all included smokers (n ϭ 31) had a sedentary life style, compared with the non-COPD group, the COPD group had statistically significantly lower physical activity scores (see Table 1 ). The above result was similar to that reported by Amorim et al, 57 where the COPD group (n ϭ 40), when compared with the non-COPD group (n ϭ 40), had a significantly greater limitation in activities of daily living 58 (33 Ϯ 11 vs 21 Ϯ 2, respectively).
Many studies have highlighted the importance of HRQOL in the evaluation of COPD severity and support the view that it should be considered, in addition to lung function, to better assess subjects with COPD. 59, 60 According to some guidelines, 2,6 the aim of clinical control in subjects with COPD includes HRQOL goals (improve QOL and increase physical and emotional participation in everyday activities) in addition to clinical goals. The usefulness of QOL measures is indisputable in the field of descriptive epidemiology. 2 In clinical practice, it can strengthen the doctor-patient relationship by emphasizing the interest that one carries to the consequences of the disease/symptoms in the patient's daily life. From a public health perspective, it is important to determine the level of physical activity to provide a theoretical basis for the development of appropriate policies and programs to enhance health and prevent the many complications attending physical inactivity. 61 Physical activity remains the best way to maintain body wellness, to ensure daily activities, and to keep good cardiopulmonary function and thus daily physical activity. Physical activity and exercise have been demonstrated to promote health and to avoid and reduce health problems, such as vascular and inflammatory diseases, and to assist with weight management. 62 Integrative Vision: BODE Index. No significant difference was found between the 2 groups' BODE indexes (see Table 3 ). The BODE index captures the multidimensional manifestations of COPD. 11 It is a valuable tool not only in the assessment of severity and progression of COPD, but also in evaluating the response to medical interventions. 63 How Can the Impairment of the COPD Smokers' 6MWD Be Explained? Several hypotheses can be advanced: alteration of the cardiorespiratory and vascular systems and myopathy. Below is a brief discussion of these hypotheses.
Spirometric data are predictors of 6MWD. 28 The present study suggests that the alteration of the resting FEV 1 and mid-maximal expiratory flow data observed in the COPD group when compared with the non-COPD group (see Table 2 ) could explain the marked difference between their 6MWDs. The alteration of the initial spirometric function limits breathing reserve 30 ; thus, the lungs may be a factor limiting the 6MWD. 30 Hypoxemia, known as a classic muscle deterioration factor, 64 cannot be retained as a hypothesis, since the 2 groups have similar S pO 2 data and include similar percentages of smokers with a clinical desaturation (see Table 3 ). Cardiovascular data (such as heart rate and blood pressures) are predictors of 6MWD. 65, 66 However, they cannot be advanced as an explanation, since the 2 groups have similar heart rate and blood pressure data and include similar percentages of smokers with chronotropic insufficiency.
Myopathy is an alteration of the functional, morphological, and metabolic qualities of muscle tissue. 67 It could be the result of numerous alterations, with the main ones being corticosteroid use, sedentary lifestyle, oxidative stress, inflammation, and apoptosis. 68 The corticosteroidinduced myopathy 69 hypothesis is not retained, since corticosteroid use was a non-inclusion criterion. Sedentary lifestyle is known as a predictor of 6MWD decline in healthy subjects 39 and in subjects with COPD 70 . Indeed, it has been shown that physical inactivity leads to a change in the typology with increased muscle fiber type II depending on the type I fibers. 71 Since the physical activity scores of COPD group were significantly lower than these of the non-COPD group (see Table 1 ), the authors can speculate that sedentary life style is a cause of structural changes and muscle metabolism. 72 Oxidative stress is known as a major cause of myopathy in subjects with COPD. 67, 73 The present paper supports this hypothesis, since the COPD group, when compared with the non-COPD group, has a lower glutathione level (Fig. 1B) . In addition, some significant correlations were found between oxidative stress biomarkers (eg, glutathione) and 6MWD in the non-COPD group and between antioxidant biomarkers (eg, malondialdehyde) in the COPD group (see Table  4 ). Moreover, a significant correlation was found between leisure score and F ENO , recognized as an oxidative biomarker that integrates both airway inflammation and lung function changes 24, 25 (see Table 4 ). Inflammation and apoptosis are also known as major causes of myopathy in subjects with COPD. 68 These 2 hypotheses were not evaluated in the present paper.
No significant correlation was found between the BODE index and the measured oxidative stress biomarker data in both groups (see Table 4 ). These results were partially consistent with those of Folchini et al, 35 who correlated BODE index and some oxidative stress biomarkers (glutathione, thiobarbituric acid-reactive substances, homocysteine, superoxide dismutase and catalase), and the only significant correlation was found between thiobarbituric acid-reactive substances and BODE index (r ϭ 0.51) of the COPD group. 35 How Can We Explain the Impairment of the COPD Smokers' QOL? Oxidative stress can be advanced as a hypothesis. In the present study, positive and significant correlation was found between the malondialdehyde and QOL score of the COPD group (see Table 4 ). This association, although internationally accepted for a long period of time, is currently under extensive research, due to the increasing appreciation of the relevant oxidative stress negative role in the prognosis and HRQOL of subjects with COPD. 6, 74 
Conclusions
Compared with the non-COPD group of smokers, the COPD group had a marked decrease in 6MWD and in QOL score. Stress oxidative biomarkers were correlated with 6MWD (malondialdehyde for the COPD group and glutathione for the non-COPD group) and QOL scores (malondialdehyde for the COPD group and F ENO for the non-COPD group).
